Clinical trial
A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)
NCT00092352 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00092352 |
|---|---|
| Title | A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219) |
| Official title | A Randomized, Placebo-Controlled, Parallel-Group, Double -Blind Study to Evaluate the Safety and Efficacy of Rofecoxib 12.5 mg and Celecoxib 200 mg in Patients With Osteoarthritis of the Knee |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoarthritis |
| Intervention type | Drug |
| Interventions | MK0966, rofecoxib, Comparator: celecoxib, placebo |
| Enrollment | 395 |
| Start date | Apr 29, 2003 |
| Primary completion | Dec 1, 2003 |
| Completion | Dec 1, 2003 |
| First posted | Sep 27, 2004 |
| Last update posted | May 9, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: